Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Boehringer Ingelheim Adds $149 Million to its Investment in China

publication date: Oct 23, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Boehringer Ingelheim of Germany will invest $149 million in China with the goal of increasing its market share in China’s pharmaceutical market. The company will use the money to expand the capacity at its existing drug production facility in Shanghai's Zhangjiang High-Tech Park, and it will also establish an R&D facility. More details...



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners